While previous studies have highlighted impacts of maternal factors such as chronic infection (including HIV, malaria), malnutrition, and metabolic disease on FcRn-mediated transplacental transfer [13], this is the first study to highlight a potential negative impact of corticosteroid use during pregnancy on placental antibody transfer in biologic and immunomodulator-exposed patients. Here, FCGRT is linked to metabolic disease.